Li Yang, Wu Jian-Hui, Li Cheng-Peng, Liu Bo-Nan, Tian Xiu-Yun, Qiu Hui, Hao Chun-Yi, Lv Ang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery/Sarcoma Center, Peking University Cancer Hospital & Institute, Beijing, China.
Front Oncol. 2022 Oct 27;12:950418. doi: 10.3389/fonc.2022.950418. eCollection 2022.
Peritoneal sarcomatosis (PS) could occur in patients with retroperitoneal sarcomas (RPS). This study aimed to expand the understanding of PS on its characteristics and prognostic role, and develop a nomogram to predict its occurrence preoperatively.
Data of 211 consecutive patients with RPS who underwent surgical treatment between 2011 and 2019 was retrospectively reviewed. First, the clinicopathological characteristics of PS were summarized and analyzed. Second, the disease-specific survival (DSS) and recurrence-free survival (RFS) of patients were analyzed to evaluate the prognostic role of PS. Third, preoperative imaging, nearly the only way to detect PS preoperatively, was combined with other screened risk factors to develop a nomogram. The performance of the nomogram was assessed.
Among the 211 patients, 49 (23.2%) patients had PS with an incidence of 13.0% in the primary patients and 35.4% in the recurrent patients. The highest incidence of PS occurred in dedifferentiated liposarcoma (25.3%) and undifferentiated pleomorphic sarcoma (25.0%). The diagnostic sensitivity of the preoperative imaging was 71.4% and its specificity was 92.6%. The maximum standardized uptake value (SUVmax) was elevated in patients with PS (P<0.001). IHC staining for liposarcoma revealed that the expression of VEGFR-2 was significantly higher in the PS group than that in the non-PS group (P = 0.008). Survival analysis (n =196) showed significantly worse DSS in the PS group than in non-PS group (median: 16.0 months vs. not reached, P < 0.001). In addition, PS was proven as one of the most significant prognostic predictors of both DSS and RFS by random survival forest algorithm. A nomogram to predict PS status was developed based on preoperative imaging combined with four risk factors including the presentation status (primary vs. recurrent), ascites, SUVmax, and tumor size. The nomogram significantly improved the diagnostic sensitivity compared to preoperative imaging alone (44/49, 89.8% vs. 35/49, 71.4%). The C-statistics of the nomogram was 0.932, and similar C-statistics (0.886) was achieved at internal cross-validation.
PS is a significant prognostic indicator for RPS, and it occurs more often in recurrent RPS and in RPS with higher malignant tendency. The proposed nomogram is effective to predict PS preoperatively.
腹膜肉瘤病(PS)可发生于腹膜后肉瘤(RPS)患者。本研究旨在加深对PS的特征及其预后作用的理解,并开发一种列线图以术前预测其发生情况。
回顾性分析2011年至2019年间连续接受手术治疗的211例RPS患者的数据。首先,总结并分析PS的临床病理特征。其次,分析患者的疾病特异性生存(DSS)和无复发生存(RFS)情况,以评估PS的预后作用。第三,将术前成像(术前检测PS的几乎唯一方法)与其他筛选出的风险因素相结合,开发列线图。评估列线图的性能。
在211例患者中,49例(23.2%)发生PS,原发患者发病率为13.0%,复发患者发病率为35.4%。PS发病率最高的是去分化脂肪肉瘤(25.3%)和未分化多形性肉瘤(25.0%)。术前成像的诊断敏感性为71.4%,特异性为92.6%。PS患者的最大标准化摄取值(SUVmax)升高(P<0.001)。脂肪肉瘤的免疫组化染色显示,PS组VEGFR-2的表达明显高于非PS组(P = 0.008)。生存分析(n =196)显示,PS组的DSS明显差于非PS组(中位数:16.0个月对未达到,P < 0.001)。此外,通过随机生存森林算法证明PS是DSS和RFS最重要的预后预测因素之一。基于术前成像结合包括表现状态(原发与复发)、腹水、SUVmax和肿瘤大小在内的四个风险因素,开发了一种预测PS状态的列线图。与单独的术前成像相比,列线图显著提高了诊断敏感性(44/49,89.8%对35/49,71.4%)。列线图的C统计量为0.932,并在内部交叉验证中获得了相似的C统计量(0.886)。
PS是RPS的一个重要预后指标,在复发的RPS和恶性倾向较高的RPS中更常发生。所提出的列线图在术前预测PS方面是有效的。